

The Power of Choice in HR+, HER2- ABC

A Case Continuum

ESMO Breast Cancer 2020 • Industry Satellite Symposium
Friday, 08 May 2020 • 13:00-14:00
Room: Munich, Hub27 Berlin • Berlin, Germany



Objectives

Discuss and increase awareness of recent advances and considerations in the treatment and management of HR+, HER2- ABC including:

- Overall survival data with CDK4/6 inhibitors
- Targeting PI3K and *PIK3CA* mutation testing
- Supporting patient care



Agenda

	Topic	Faculty
13:00-13:05	Welcome and Introductions	Chair: Dejan Juric, MD
13:05-13:20	Introduction of the Case and Panel Discussion	Dejan Juric, MD All Faculty Panel
13:20-13:35	Presentation and Selection of a First-Line Therapy Spotlight Presentation: Fulvestrant as Combination Partner in Both First and Second Line	Fatima Cardoso, MD Dejan Juric, MD All Faculty Panel
13:35-13:45	Switching to a Second-Line Treatment	Hans-Christian Kolberg, MD
13:45-13:50	Putting the Case in Context	Dejan Juric, MD
13:50-14:00	Panel Q&A and Closing Remarks	Moderator: Dejan Juric, MD All Faculty Panel



This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.

Novartis Pharma AG
CH-4002 Basel Switzerland © Novartis 2020 02/20 G-RIB-1226985